Download a 29-page Preview Guide (pdf) to the 2013 National Rx Drug Abuse Summit.
|Tuesday, April 2, 2013|
|U.S. Response to Rx Drug Abuse Epidemic / 8:00 am – 10:00 am|
|Moderator||Dr. Robert DuPont
Clinical Professor of Psychiatry, Georgetown University School of Medicine
|Presenters||Hon. Harold “Hal” Rogers (KY-5th)
Chair, U.S. House of Representatives Committee on Appropriations and Co-Founder and Co-Chair, Congressional Caucus on Prescription Drug Abuse
R. Gil Kerlikowske
Director, White House Office of National Drug Control Policy
Dr. Margaret Hamburg
Commissioner, U.S. Food and Drug Administration (FDA)
Dr. Thomas Frieden
Director, Centers for Disease Control and Prevention (CDC)
|Description||Congressman Rogers formed the Congressional Caucus on Prescription Drug Abuse in 2009 and has been a tireless advocate in the fight against the ravages of Rx drug abuse. He championed Operation UNITE to impact this epidemic within his Congressional District in 2003 and knows all too well the destruction it can cause. He has led many fights on this issue and in early 2013 received the Congressional Leadership Award from the Community Anti-Drug Coalitions of America (CADCA) for his unwavering commitment to keeping America’s youth drug and alcohol free.
Director Kerlikowske was nominated by President Obama and confirmed by the U.S. Senate as Director of the Office of National Drug Control Policy. In his position, Mr. Kerlikowske coordinates all aspects of Federal drug control programs and implementation of the President’s National Drug Control Strategy. Mr. Kerlikowske brings 37 years of law enforcement and drug policy experience to the position. He most recently served nine years as the Chief of Police for Seattle, Washington.
Dr. Hamburg became the 21st commissioner of food and drugs on May 18, 2009. The second woman to be nominated for this position, Dr. Hamburg has conducted research on neuroscience at Rockefeller University, studied neuropharmacology at the National Institute of Mental Health, and is the top official of the Food and Drug Administration (FDA).
Dr. Frieden became Director of the Centers for Disease Control and Prevention (CDC) and Administrator of the Agency for Toxic Substances and Disease Registry (ATSDR) in June 2009. Among his many career accomplishments, Dr. Frieden led New York City’s program that rapidly controlled tuberculosis, including reducing cases of multidrug-resistant tuberculosis by 80 percent and worked in India where he treated more than 10 million patients and saved more than one million lives.
|Learning Objectives||1. Define the public health threat of prescription drug abuse.
2. State the latest recommendations by the CDC to limit prescription drug abuse.
3. Outline the FDA task force’s initiatives to combat the misuse, abuse and addiction of prescription drugs.
|Realities of Addiction / 5:00 pm – 6:00 pm|
President & CEO, Operation UNITE
|Presenter||Dr. Nora Volkow
Director, National Institute on Drug Abuse (NIDA)
|Description||Dr. Volkow is Director of the National Institute on Drug Abuse (NIDA) at the National Institutes of Health (NIH). She pioneered the use of brain imaging to investigate the effects of drugs in the human brain and has demonstrated that drug addiction is a brain disease. Dr. Volkow has received multiple awards, including membership in the Institute of Medicine, named one of Time Magazine’s “Top 100 People Who Shape our World”, included as “One of the 20 People to Watch” by Newsweek magazine, and named “Innovator of the Year” by U.S. News & World Report.|
|Learning Objectives||1. Identify recent increasing trends in the misuse and abuse of prescription drugs.
2. Describe the ways in which the most commonly abused prescription drug classes affect the brain and body.
3. Explain strategies being developed and implemented that will increase awareness of the growing problem of addiction.
|Wednesday, April 3, 2013|
|The Cost of Rx Drug Abuse / 8:00 am – 9:15 am|
Reporter, The Wall Street Journal
|Panelists||Gen. Arthur T. Dean
Chairman and CEO, Community Anti-Drug Coalitions of America (CADCA)
John J. Dreyzehner, MD, MPH, FACOEM
Commissioner, Tennessee Department of Health
Executive Director, Coalition Against Insurance Fraud
Deputy District Attorney, Major Narcotics Division, Office of the Los Angeles County District Attorney
|Description||Industry research shows that employers and insurers spent more than $1.4 billion on narcotics for workers’ compensation in 2012. According to the Coalition Against Insurance Fraud, “doctor shoppers” cost insurers $10,000 to $15,000 per patient; the toll in lost productivity is $42 billion, the criminal justice bill is $8.2 billion, and the cost of prescription painkiller abuse for insurers is $72.5 billion.
While there are numerous financial costs for the epidemic of Rx drug abuse there is also a human cost that, in many cases, is even greater than the financial considerations. Join this panel of experts who will examine the complete cost of Rx drug abuse and provide their thoughts on how we can all do more to decrease the devastating costs for both the financial and human toll it is taking on our nation, states and communities.
|Learning Objectives||1. Investigate the national epidemiology of current prescription drug abuse.
2. Demonstrate communication techniques for dialogue to ensure optimal care of patients and the community.
3. Outline management strategies for prescription drug abuse considering clinical, economic and humanistic factors.
|Forum of the Congressional Caucus on Prescription Drug Abuse / 9:30 am – 11:00 am|
|Moderator||Steve Pasierb, MEd
President and CEO, The Partnership at Drugfree.org
|Panelists||Hon. Harold “Hal” Rogers (KY-5th)
Republican, Chair, U.S. House Committee on Appropriations, and Co-Founder and Co-Chair, Congressional Caucus on Prescription Drug Abuse
Hon. Michael Grimm (NY-11th)
Republican, Member, U.S. House Committee on Financial Services
Hon. William R. “Bill” Keating (MA-9th)
Democrat, Member, U.S. House Committees on Homeland Security and Foreign Affairs
Hon. Daniel Webster (FL-10th)
Republican, Member, U.S. House Rules Committee
|Description||The bi-partisan Congressional Caucus on Prescription Drug Abuse was established in 2010 to raise awareness of abuse and to work toward innovative and effective policy solutions, incorporating treatment, prevention, law enforcement and research. Caucus members collaborate to gather relevant information from stakeholders involved in prescription drug initiatives and disseminate their findings and recommendations to fellow Congressional members.
This forum will include presentations from each of the Congressional members regarding what is occurring in Washington that can make a positive impact on curbing prescription drug abuse. Currently there are two bills that have been introduced by members of the Caucus related to prescription drug abuse: HR 672, the Prescription Drug Abuse Prevention and Treatment Act, and HR 486, the Stop Tampering of Prescription Pills Act of 2013.
Following these presentations there will be a question-and-answer session to hear concerns and comments from those impacting the issue on the front lines.
|Learning Objectives||1. Define the purpose of the Congressional Caucus on Prescription Drug Abuse.
2. Express opportunities for stakeholders to impact legislative policies and laws.
3. Explain current bills in the U.S. House of Representatives to address the prescription drug abuse issue.
|Thought Leaders Perspective / 11:15 am – 12:30 pm|
|Moderator||Steve Pasierb, MEd
President and CEO, The Partnership at Drugfree.org
|Presenters||Hon. Michael R. Bloomberg
Mayor, City of New York
Hon. Pam Bondi
Attorney General, State of Florida
|Description||Not afraid to tackle difficult problems, Mayor Michael Bloomberg leads a city that is safer, stronger, and greener than ever. Among his many achievements as Mayor is reducing crime by more than 30 percent; high school graduation rates are up more than 40 percent since 2005; teen smoking is down more than 50 percent; and, since October 2009, New York has added as many private sector jobs as the next 10 largest U.S. cities combined. His passion for public health has led to ambitious new health strategies that have become national models, including a ban on smoking in all indoor workplaces, as well as at parks and beaches.
Under Mayor Bloomberg’s leadership, guidelines were developed for all of the City’s public hospital emergency departments that ban long-acting opioid painkillers;can only prescribe up to a three-day supply of opioids; and will not refill lost, stolen or destroyed prescriptions. In addition to the prescribing guidelines, he created N.Y.C. RxStat, which will work to combine and use relevant public health and public safety data to combat the problem of prescription painkiller abuse. He has worked to raise awareness of painkiller abuse through public education campaigns and has worked with the state to create an improved Prescription Drug Monitoring Program.
Because of these efforts, today, life expectancy in New York is 29 months longer than it was before Mayor Bloomberg took office.
A native of Tampa, Attorney General Bondi is focused on protecting Floridians and upholding Florida’s laws and the Constitution. Since taking office in 2011, Bondi has worked to rid Florida of deadly synthetic drugs; focused attention on the problem of human trafficking; strengthened penalties to stop pill mills; and, addressed the problem of newborns exposed to the prescription drugs their mothers abused.
Under Attorney General Bondi’s leadership, Florida has made great strides in fighting the prescription drug abuse problem. When she took office, approximately seven people were dying every day as the result of prescription drug overdoses. Attorney General Bondi worked to rid the state of the pill mills that were once a primary source for prescription drug diversion in the Eastern United States. Within two years after making it one of her priorities, Florida saw a decrease in prescription drug deaths for the first time in nearly a decade.
|Learning Objectives||1. Analyze the successes of the Mayor’s Task Force on Prescription Painkiller Abuse to prevent the abuse and misuse of prescription drugs.
2. Outline the Emergency Department prescription guidelines adopted by New York City in January 2013.
3. Define the initiatives of Florida’s attorney general in limiting the reach of prescription drug abuse.
|Prevention and Prosecution / 4:30 pm – 5:30 pm|
President & CEO, Operation UNITE
|Presenters||Frances M. Harding
Director, Center for Substance Abuse Prevention (CSAP) of the Substance Abuse and Mental Health Services Administration (SAMHSA)
Joseph T. Rannazzisi
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration (DEA)
|Description||Director Harding serves as Director of CSAP and is recognized as one of the nation’s leading experts in the field of alcohol and drug policy. She also serves as the lead for SAMHSA’s Strategic Initiative on the Prevention of Substance Abuse and Mental Illness, which will create prevention prepared communities where individuals, families, schools, faith-based organizations, workplaces, and communities take action to promote emotional health and reduce the likelihood of mental illness, substance abuse including tobacco, and suicide.
Mr. Rannazzisi is a career Special Agent who held positions that included Clandestine Lab Coordinator, Task Force Group Supervisor (Detroit Field Division), Assistant Special Agent in Charge (Detroit Field Division), Section Chief (Dangerous Drugs and Chemical Section) and Deputy Chief (Enforcement Operations). He is responsible for overseeing and coordinating major pharmaceutical, precursor chemical, clandestine laboratory and synthetic drug investigations; the drafting and promulgating of regulations; establishing drug production quotas; and serves as liaison to the pharmaceutical industry, international governments, state governments, federal agencies, and law enforcement agencies.
|Learning Objectives||1. Outline how to improve access and quality of care through strategic planning and community-wide coordination with local, state and federal agencies.
2. Identify opportunities for collaborative partnerships to prevent prescription drug abuse.
3. Examine reasons for the increasing rate of diversion and abuse of prescription drugs.